Vemurafenib as first line therapy in BRAF-mutated Langerhans cell histiocytosis

Affiliations

• ¹ Department of Internal Medicine and French Reference Center for Rare Auto-immune and Systemic Diseases, Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié-Salpêtrière Hospital, Paris, France; Université Pierre et Marie Curie, UPMC University Paris 6, Paris, France. Electronic address: julien.haroche@psl.aphp.fr.
• ² Department of Internal Medicine and French Reference Center for Rare Auto-immune and Systemic Diseases, Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié-Salpêtrière Hospital, Paris, France; Université Pierre et Marie Curie, UPMC University Paris 6, Paris, France.
• ³ Research Unit (EA) EA4340 and Pathology Laboratory, Versailles University and AP-HP, Boulogne, France.
• ⁴ Department of Pediatrics, AP-HP, Centre de Référence des Histiocytoses, Hôpital Trousseau, Paris, France.